Busca avançada
Ano de início
Entree
(Referência obtida automaticamente do Web of Science, por meio da informação sobre o financiamento pela FAPESP e o número do processo correspondente, incluída na publicação pelos autores.)

Immunological correlates of favorable long-term clinical outcome in multiple sclerosis patients after autologous hematopoietic stem cell transplantation

Texto completo
Autor(es):
Mostrar menos -
Arruda, Lucas C. M. ; de Azevedo, Julia T. C. ; de Oliveira, Gislane L. V. ; Scortegagna, Gabriela T. ; Rodrigues, Evandra S. ; Palma, Patricia V. B. ; Brum, Doralina G. ; Guerreiro, Carlos T. ; Marques, Vanessa D. ; Barreira, Amilton A. ; Covas, Dimas T. ; Simoes, Belinda P. ; Voltarelli, Julio C. ; Oliveira, Maria Carolina ; Malmegrim, Kelen C. R.
Número total de Autores: 15
Tipo de documento: Artigo Científico
Fonte: Clinical Immunology; v. 169, p. 47-57, AUG 2016.
Citações Web of Science: 16
Resumo

High dose immunosuppression followed by autologous hematopoietic stem cell transplantation (AHSCT) induces prolonged clinical remission in multiple sclerosis (MS) patients. However, how patient immune profiles are associated with clinical outcomes has not yet been completely elucidated. In this study, 37 MS patients were assessed for neurological outcomes, thymic function and long-term immune reconstitution after AHSCT. Patients were followed for a mean (SD) of 68.5 (13.9) months post-transplantation and were retrospectively clustered into progression- and non-progression groups, based on Expanded Disease Status Scale (EDSS) outcomes at last visit. After AHSCT, both patient groups presented increased regulatory T-cell subset counts, early expansion of central- and effector-memory CD8(+) T-cells and late thymic reactivation. However, the non-progression group presented early expansion of PD-1 CD8(+) T-cells and of PD-1-expressing CD19(+) B-cells. Here, we suggest that along with increased numbers of regulatory T-cell subsets, PD-1 inhibitory signaling is one possible immunoregulatory mechanism by which AHSCT restores immune tolerance in MS patients. (C) 2016 Elsevier Inc. All rights reserved. (AU)

Processo FAPESP: 08/57877-3 - Instituto Nacional de Ciência e Tecnologia em Células-Tronco e Terapia Celular - INCTC
Beneficiário:Roberto Passetto Falcão
Linha de fomento: Auxílio à Pesquisa - Temático
Processo FAPESP: 13/08135-2 - CTC - Centro de Terapia Celular
Beneficiário:Dimas Tadeu Covas
Linha de fomento: Auxílio à Pesquisa - Centros de Pesquisa, Inovação e Difusão - CEPIDs